Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of N-Acetyl-L-Leucine on GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease): A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study

NCT03759665 is registered in ClinicalTrials.gov with IntraBio Inc as lead sponsor.

NCT NCT03759665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03759665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of N-Acetyl-L-Leucine on GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease): A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study
Lead sponsor
IntraBio Inc
Phase
Phase 2
Overall status
Completed
Start date
June 7, 2019
Completion date
January 9, 2023
Enrollment
30 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

gm2 gangliosidosis, sandhoff disease, tay-sachs disease